Entities / Company
Alto Neuroscience (United States).
company in Los Altos, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 22
What's happening
Gone quiet
No new reports in 90+ days-
Alto Neuroscience is leveraging Trump-era tariffs and AI trends to advance its drug candidate ALTO-203 for Major Depressive Disorder (MDD).Some support2 reports1 development inside
-
Amit Etkin was appointed Founder and CEO of Alto Neuroscience on August 14, 2025.Some support3 reports
-
Alto Neuroscience is involved in a PAX-D study funded by NIHCR and conducted at the University of Oxford.Speculative1 report
-
Stifel reiterated a 'Buy' rating on Alto Neuroscience (ANRO) on July 29, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Connections
The 1 strongest of 22, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Amit Etkin Structural
Amit Etkin serves as the founder and CEO of Alto Neuroscience.
History
Events by the month they beganJune 2026
4 events- Alto Neuroscience is leveraging Trump-era tariffs and AI trends to advance its drug candidate ALTO-203 for Major Depressive Disorder (MDD).
- Amit Etkin was appointed Founder and CEO of Alto Neuroscience on August 14, 2025.
- Alto Neuroscience is involved in a PAX-D study funded by NIHCR and conducted at the University of Oxford.
- Stifel reiterated a 'Buy' rating on Alto Neuroscience (ANRO) on July 29, 2025.